Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Combined With QL1706 and Bevacizumab in Unresectable HER2-Negative Intrahepatic Cholangiocarcinoma
NCT07841574Phase 2Recruiting
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in intrahepatic cholangiocarcinoma (ICC). Started Jun 2026; status: recruiting.
02
Drugs
QL1706
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT07841574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07841574.